Please login to the form below

Not currently logged in
Email:
Password:

Testing for new Alzheimer's treatment

American pharma company Eli Lilly & Co announced on March 31 the start of a phase III clinical trial for a new Alzheimer's treatment.
American pharma company Eli Lilly & Co announced on March 31 the start of a phase III clinical trial for a new Alzheimer's treatment.

The new treatment, known as LY450139, will be tested in the IDENTITY (interrupting Alzheimer's Dementia by Evaluating Treatment of Amylold Pathology) trial.

Lilly claims that LY450139 could slow the onset of mild-to-moderate Alzheimer's disease and give patients preserved functionality and quality of life.

During the course of the double-blind, placebo-controlled study, 1,500 patients will take part in the trials in the US and 21 additional countries over the course of 21 months.

Dr Eric Siemers, medical director of Alzheimer's disease research for Lilly, said: "Alzheimer's is a devastating disease that destroys brain cells, affecting everything from a patient's memory to their work and social life. Currently available medications treat the symptoms of Alzheimer's disease but have not been shown to change its underlying progression, creating an urgent unmet medical need."

LY450139 is an investigational gamma secretase inhibitor and has been developed to counteract the degenerative progression of Alzheimer's by excreting an enzyme that creates a sticky protein.

Siemers said that Lilly hopes, "that LY450139 will represent an advance in the attempt to slow the progression of this fatal disease".

31st March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics